Clenbuterol Sopharma - instructions for use, dose, side effects, contraindications

Active substanceClenbuterolClenbuterol

Similar drugsTo uncover

Clenbuterol

syrup inwards

Balkanfarm - Troyan AD Bulgaria

Clenbuterol

syrup inwards

Sopharma, AO Bulgaria

Clenbuterol Sopharma

pills inwards

Sopharma, AO Bulgaria

Dosage form: & nbsppills

Composition:

1 tablet contains:

active substance: clenbuterol hydrochloride 0.02 mg;

Excipients: lactose monohydrate 70.00 mg, wheat starch 31.48 mg, cellulose microcrystalline 48.50 mg, silicon dioxide colloid 2.00 mg, magnesium stearate 2.00 mg, povidone (povidone K25) 6.0 mg.

Description:

Round flat tablets with a facet and delicate risk on one side, white or almost white.

Pharmacotherapeutic group:Bronchodilator - beta2-adrenomimetic selective

ATX: & nbsp

R.03.A.C.14 Clenbuterol

Pharmacodynamics:

Selective β₂-adrenostimulator, has a bronchodilator and secretolytic effect. Excites β₂-adrenoceptors, stimulates adenylate cyclase, increases in cells the content of cyclic adenosine monophosphate (cAMP). The latter has an effect on the protein kinase system, as a result of which myosin is deprived of the ability to bind to actin and bronchodilation occurs. It inhibits the release from the mast cells of mediators, which cause bronchospasm and inflammation of the bronchi.

Prevents bronchospasm caused by histamine, serotonin and acetylcholine. Reduces edema or stagnation in the bronchi, improves mucociliary clearance. The secretolitic effect of the drug is associated with a decrease in the viscosity of the sputum and the relief of its secretion. It causes the expansion of the vessels of the brain and skeletal muscles. Possesses tocolytic action. Side effects are associated with its ability, albeit poorly, to induce excitation of β₁β-adrenoreceptors of the heart, as a result of which a positive foreign and chronotropic effect is manifested.

Has a slight anabolic effect, can increase body temperature.

The maximum effect of the drug is observed after 2-3 hours and lasts up to 6-8 hours.

Pharmacokinetics:

Quickly and completely absorbed in the gastrointestinal tract. Metabolized to a small extent in the liver, resulting in the formation of 8 metabolites that do not have pharmacological activity. The release from the plasma passes in two phases. The half-life of the first phase is 1 hour, the second - 34 hours. Mostly it is excreted unchanged through the kidneys, with 87% of the dose taken within 168 hours.

Indications:

Chronic obstructive pulmonary disease, broncho-obstructive syndrome, bronchial asthma.

Contraindications:

Hypersensitivity to clenbuterol or to auxiliary substances of the drug, thyrotoxicosis, tachyarrhythmia, hypertrophic obstructive cardiomyopathy, myocardial infarction (acute phase), severe ischemic heart disease, lactase insufficiency, lactose intolerance, glucose-galactose malabsorption, children under 6 years, pregnancy (I and III trimester).

Carefully:

Hyperthyroidism, myocardial infarction in anamnesis, coronary heart disease, arterial hypertension, prostatic hypertrophy, diabetes mellitus, II trimester of pregnancy.

Pregnancy and lactation:

It is necessary to avoid prescribing the drug in the first 3 months of pregnancy due to possible adverse effects on fetal development. His appointment is not recommended in the last months of pregnancy and during childbirth due to the presence of tocolytic action of the drug and possible suppression of the tone of the uterus.

There were no special clinical studies of the penetration of the drug into breast milk,in connection with which its appointment to lactating women is not recommended.

Dosing and Administration:

Inside.

Adults: on 0,02 mg (on one tablet) 2 times a day (in the morning and in the evening).

Supportive dose of 0.01 mg (1/2 tablets) 2 times a day.

In more severe conditions, in the first days, 0.04 mg (two tablets) are prescribed 2 times a day (morning and evening).

After improving the patient's condition, the dose of the drug should be reduced.

Children from 6 to 12 years: 0.01 mg (1/2 tablet) 2 times a day (morning and evening).

Children over 12 years old: 0.01 mg (1/2 tablet) 2-3 times a day or 0.02 mg (1 tablet) 2 times a day (morning and evening).

Side effects:

From the central nervous system: feelings of fear, mental disorders, hyperkinesis, sleep disorders, headache, redness of the face, sweating, trembling and anxiety, dizziness, patients with Parkinson's disease may experience increased tremor and muscle rigidity.

From the cardiovascular system: palpitations, tachycardia, decreased or (more often) increased blood pressure.

From the urinary system: urinary retention, associated with spasm of renal vessels and sphincter of the bladder.

From the side of metabolism: as a result of stimulation of glycogenolysis in patients with diabetes mellitus, hyperglycemia may appear. The appearance of this side effect requires a reduction in the dose of the drug without discontinuing treatment.

From the digestive system: dry mouth, nausea.

Allergic reactions are possible: skin rash, hives.

Others: hypokalemia.

Overdose:

It is manifested by increased adverse reactions: arrhythmia, tachycardia, increased blood pressure, cardialgia, tremor of the extremities. There is a danger of hypokalemia after an overdose, so it is necessary to monitor the serum potassium concentration.

Treatment: gastric lavage, the reception of activated charcoal, the use of water-salt solutions, symptomatic (including with caution selective beta-blockers).

Interaction:

Beta-blockers due to antagonism with clenbuterol may reduce or eliminate its bronchodilator effect.

Reduces the effect of hypoglycemic drugs.

When used simultaneously with cardiac glycosides, monoamine oxidase inhibitors and theophylline, the risk of cardiac rhythm disturbances increases.

Reduces the effectiveness of antihypertensive drugs.

The effect of the drug is potentiated by tricyclic antidepressants, beta-adrenomimetics and anticholinergics. In combination with sympathomimetic drugs, toxicity increases.

Halothane and other halogenated hydrocarbon anesthetics, as well as cyclopropane, can potentiate the pro-arrhythmic effect of β_2-adrenomimetics, including clenbuterol.

Special instructions:

When treating patients with diabetes, periodic monitoring of blood glucose levels is necessary. The use of the drug may lead to an increase in body weight due to the presence of anabolic effect, and when prescribed to athletes the drug can cause a positive result in the conduct of doping control.

During treatment with the drug, the development of resistance and the syndrome of "ricochet" is possible.

The composition contains wheat starch. Wheat starch may contain gluten, but only in a small amount, and is therefore considered safe for individuals with celiac disease.

Effect on the ability to drive transp. cf. and fur:In connection with the possibility of tremors, dizziness and weakness, during the treatment with the drug it is necessary to refrain from carrying out potentially dangerous activities requiring special attention and quick reactions (driving and other vehicles, working with moving mechanisms).

Form release / dosage:

Tablets, 0.02 mg.

Packaging:

For 10 tablets in a blister of PVC film / aluminum foil.

For 5 blisters together with instructions for use in a pack of cardboard.

Storage conditions:

In dry, the dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children!

Shelf life:

3 years.

Do not use after expiry date.

Terms of leave from pharmacies:On prescription

Registration number:LP-001173

Date of registration:11.11.2011 / 14.11.2016

Expiration Date:Unlimited

The owner of the registration certificate:Sopharma, AOSopharma, AO Bulgaria

Manufacturer: & nbsp

SOPHARMA, AD Bulgaria

Representation: & nbspSOFARMA SA SOFARMA SA Bulgaria

Information update date: & nbsp25.01.2018

Illustrated instructions

Instructions

Clenbuterol Sopharma (Clenbuterol Sopharma)